Business Context and Reporting Period
This Form 8-K is a current report filed by Oncocyte Corporation (not Insight Molecular Diagnostics Inc.) on March 24, 2025. The filing serves to announce the company's financial results for the three and twelve months ended December 31, 2024. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are referenced as being included in the attached press release (Exhibit 99.1) but are not present in the filing text itself.
Material Changes
The filing text does not provide specific details on material changes versus prior periods. It only indicates that the results for the periods ended December 31, 2024, have been announced.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It explicitly states that the information in Item 2.02 and Exhibit 99.1 is "furnished" and not "filed" for purposes of Section 18 of the Exchange Act, meaning it is not subject to the same liabilities as filed information.
Investor Verification Checklist
- Verify the correct registrant name is Oncocyte Corporation (Ticker: OCX), as the input metadata incorrectly listed "Insight Molecular Diagnostics Inc."
- Review Exhibit 99.1 (the press release) for actual financial figures, as they are not included in the 8-K text.
- Confirm the reporting period covers the three and twelve months ended December 31, 2024.
- Note that the financial information is furnished and not deemed "filed" under Section 18 of the Exchange Act.